Antithrombotic therapy for venous stenting in Russia: Delphi consensus

Introduction: venous stenting is increasingly used in the treatment of venous stenosis and occlusion, but there is currently no consensus on the optimal antithrombotic therapy. Aim: the aim of this study was to determine the most commonly used antithrombotic treatment regimens and to improve the results of venous stenting in the Russian Federation. Methods: an electronic survey containing three clinical scenarios of venous stenting: non-thrombotic lesions, post-thrombotic syndrome and acute deep vein thrombosis (DVT) was distributed among experts in the field of venous stenting in Russia. The survey was sent to 43 experts to determine the consensus on the optimal antithrombotic therapy regimen for the above scenarios. Consensus was defined as approval or rejection of the application by >67% of respondents. Results: the survey was completed by 32 experts who practice in 19 medical centers in Russia. Three statements met the consensus criteria. Anticoagulant therapy was the preferred treatment during the first 6-12 months after venous stenting for compression venous lesions, as well as for single acute DVT. Lifelong anticoagulant therapy was recommended after recurrent DVT. There was no agreement on the role of long-term antiplatelet therapy. Conclusion: there is a consensus among experts regarding anticoagulant therapy after venous stenting. However, there is currently no consensus on the role of antiplatelet therapy.